Axsome Therapeutics (AXSM) Retained Earnings (2021 - 2026)
Axsome Therapeutics' Retained Earnings history spans 6 years, with the latest figure at -$1.4 billion for Q1 2026.
- On a quarterly basis, Retained Earnings fell 15.93% to -$1.4 billion in Q1 2026 year-over-year; TTM through Mar 2026 was -$1.4 billion, a 15.93% decrease, with the full-year FY2025 number at -$1.3 billion, down 16.31% from a year prior.
- Retained Earnings hit -$1.4 billion in Q1 2026 for Axsome Therapeutics, down from -$1.3 billion in the prior quarter.
- Over the last five years, Retained Earnings for AXSM hit a ceiling of -$448.8 million in Q1 2022 and a floor of -$1.4 billion in Q1 2026.
- Historically, Retained Earnings has averaged -$902.9 million across 5 years, with a median of -$903.9 million in 2024.
- Biggest five-year swings in Retained Earnings: crashed 48.78% in 2024 and later decreased 15.93% in 2026.
- Tracing AXSM's Retained Earnings over 5 years: stood at -$596.3 million in 2022, then plummeted by 40.12% to -$835.6 million in 2023, then plummeted by 34.37% to -$1.1 billion in 2024, then fell by 16.31% to -$1.3 billion in 2025, then decreased by 4.94% to -$1.4 billion in 2026.
- Business Quant data shows Retained Earnings for AXSM at -$1.4 billion in Q1 2026, -$1.3 billion in Q4 2025, and -$1.3 billion in Q3 2025.